The Dog Cancer Survival Guide (136 page)

Immunophenotypic characterization of canine lymphoproliferative disorders. Ruslander DA, Gebhard DH, Tompkins MB, et al.
In Vivo
11:169-72, 1997

Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma. Lana SE, Jackson TL, Burnett RC, et al.
J Vet Intern Med
20:329, 2006.

Use of fine needle aspirates and flow cytometry for the diagnosis, classification, and immunophenotyping of canine lymphomas. Sozmen M, Tasca S, Carli E, et al.
J Vet Diagn Invest
17:323, 2005.

Correlation between thoracic radiographic changes and remission/survival duration in 270 dogs with lymphosarcoma. Starrak GS, Berry CR, Page RL, et al.
Vet Radiol Ultrasound
. 38:411-8, 1997

Humoral hypercalcemia of malignancy in canine lymphosarcoma. Weir EC, Norrdin RW, Matus RE, et al.
Endocrinology
122:602-8, 1988

Lymphoma Chemotherapy

Systemic therapy of cutaneous T-cell lymphoma (Mycosis fungoides and the Sezary Syndrome). Bunn PA, Hoffman SJ, Norris D, et al.
Ann Intern Med
121:592-602, 1994.

Monoclonal antibody C219 immunohistochemistry against Pglycoprotein: sequential analysis and predictive ability in dogs with lymphoma. Bergman PJ, Ogilvie GK, Powers BE.
J Vet Intern Med
10:354, 1996.

Chemotherapy of canine lymphoma with histopathological correlation: doxorubicin alone compared to COP as first treatment regimen. Carter RF, Harris CK, Withrow SJ.
J Am Anim Hosp Assoc
23:221, 1987.

Treatment of lymphoma and leukemia with cyclophosphamide, vincristine, and prednisone. Cotter SM, Goldstein MA.
J Am Anim Hosp Assoc
19:159, 1983.

Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Garrett LD, Thamm DH, Chun R, et al.
J Vet Intern Med
16:704, 2002.

Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma. Jeffreys AB, Knapp DW, Carlton WW, et al.
J Am Anim Hosp Assoc
41:221, 2005.

Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? Mac-Donald VS, Thamm DH, Kurzman ID, et al.
J Vet Intern Med
19:732, 2005

Evaluation of a discontinuous treatment protocol (VELCAPS) for canine lymphoma. Moore AS, Cotter SM, Rand WM, et al.
J Vet Intern Med
15:348, 2001.

Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin. Valerius KD, Ogilvie GK, Fettman MJ, et al.
J Am Vet Med Assoc
214:353, 1999.

The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Moore AS, Leveille CR, Reimann KA, et al.
Cancer Invest
13:475, 1995.

Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. Mealey KL, Northrup NC, Bentjen SA.
J Am Vet Med Assoc
223:1453, 1434, 2003.

Impact of Chemotherapeutic Dose Intensity and Hematologic Toxicity on First Remission Duration in Dogs with Lymphoma Treated with a Chemoradiotherapy Protocol. Vaughan A, Johnson JL, Williams, LE.
J Vet Intern Med
, 21: 1332–1339, 2007.

CCNU in the treatment of canine epitheliotropic lymphoma. Williams LE, Rassnick KM, Power HT, et al.
J Vet Intern Med
20:136, 2006.

Lymphoma Rescue Protocols

Doxorubicin for treatment of canine lymphosarcoma after development of resistance to combination chemotherapy. Calvert CA, Leifer CE.
J Am Vet Med Assoc
179:1011, 1981.

Treatment of tumor-bearing dogs with actinomycin D. Hammer AS, Couto CG, Ayl RD, et al.
J Vet Intern Med
8:236, 1994.

Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma. LeBlanc AK, Mauldin GE, Milner RJ, et al.
Vet Comp Oncol
4:21, 2006.

Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. Moore AS, London CA, Wood CA, et al.
J Vet Intern Med
13:395, 1999.

Evaluation of mitoxantrone for the treatment of lymphoma in dogs. Moore AS, London CA, Wood CA, et al.
J Am Vet Med Assoc
204:1903-5, 1994

Actinomycin D for reinduction of remission in dogs with resistant lymphoma. Moore AS, Ogilvie GK, Vail DM.
J Vet Intern Med
8:343, 1994.

MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases (1989-2000). Rassnick KM, Mauldin GE, Al-Sarraf R, et al.
J Vet Intern Med
16:576, 2002.

Treatment of relapsed canine lymphoma with doxorubicin and dacarbazine. Van Vechten M, Helfand SC, Jeglum KA.
J Vet Intern Med
4:187, 1990

Lymphoma: Other Treatment Options

A feasibility study of low-dose total body irradiation for relapsed canine lymphoma. Brown EM, Ruslander DM, Azuma C, et al.
Vet Comp Oncol
4:75, 2006.

A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAPHDC) for canine lymphoma. Frimberger AE, Moore AS, Rassnick KM, et al.
J Vet Intern Med
20:355, 2006.

Half-body radiotherapy in the treatment of canine lymphoma. Laing EJ, Fitzpatrick PJ, Binnington AG, et al.
J Vet Intern Med
3:102-8, 1989

Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T-cell lymphoma. Lupu M, Sullivan EW, Westfall TE, et al.
J Am Vet Med Assoc
228:728, 2006.

The role of radiotherapy in the treatment of lymphoma and thymoma. Meleo KA.
Vet Clin North Am Small Anim Pract
27:115-29, 1997

Effect of fish oil, arginine, and doxorubicin chemotherapy on remission and survival time for dogs with lymphoma: a double-blind, randomized placebo-controlled study. Ogilvie GK, Fettman MJ, Mallinckrodt CH, et al.
Cancer
88:1916, 2000.

Total skin electron beam irradiation for generalized cutaneous lymphoma. Prescott D.M., Gordon J.
Vet Comp Oncol
3:32, 2005.

Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma. Selting KA, Ogilvie GK, Gustafson DL, et al.
Am J Vet Res
67:145, 2006.

Chemotherapy followed by half-body radiation therapy for canine lymphoma. Williams LE, Johnson JL, Hauck ML, et al.
J Vet Intern Med
18:703, 2004.

Maintenance multivitamins (also see antioxidants and pro-oxidants for related citations)

Antioxidants and cancer therapy: a systematic review. Ladas EJ, et al.
J Clin Oncol.
2004 Feb 1;22(3):517-28. Review.

Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants? Moss RW.
Integr Cancer Ther
. 2006 Mar;5(1):63-82. Review.

Antioxidant Supplementation in Cancer: Potential Interactions with Conventional Chemotherapy and Radiation Therapy. [No author listed.] Thomas Jefferson University Hospital, Myrna Brind Center of Integrative Medicine. July, 2006. Available at:
http://jdc.jefferson.edu/cgi/viewcontent.cgi?article=1009&context=jmbcim

Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Simone CB 2nd, et al.
Altern Ther Health Med
. 2007 Jan-Feb;13(1):22-8. Review.

Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, Part 2. Simone CB 2nd, et al.
Altern Ther Health Med
. 2007 Mar-Apr;13(2):40-7. Review.

Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Conklin KA.
Nutr Cancer
. 2000;37(1):1-18. Review.

The antioxidant conundrum in cancer. Seifried HE, et al.
Cancer Res.
2003 Aug 1;63(15):4295-8. Review.

Antioxidant vitamins and minerals in prevention of cancers: lessons from the SU.VI.MAX study. Hercberg S, Czernichow S, Galan P.
Br J Nutr
. 2006 Aug;96 Suppl 1:S28-30.

A review of the interaction among dietary antioxidants and reactive oxygen species. Seifried HE, et al.
J Nutr Biochem
. 2007 Sep;18(9):567-79. Epub 2007 Mar 23. Review.

Antioxidant effects of natural bioactive compounds. Balsano C and Alisi A.
Curr Pharm Des
. 2009;15(26):3063-73. Review.

Free radicals and antioxidants in normal physiological functions and human disease. Valko M, et al.
Int J Biochem Cell Biol
. 2007;39(1):44-84. Epub 2006 Aug 4. Review.

Clinical and experimental experiences with intravenous vitamin C. Riordan NH, Riordan HD, Casciari JP.
J Orthomol Med
. 2000;15:201-213. Available at:
http://orthomolecular.org/library/jom/2000/pdf/2000-v15n04-p201.
pdf. Accessed February 12, 2007.

Mammary Tumors

Canine Mammary Gland Tumors. Henry CJ, in Henry CJ, Higginbotham ML (ed):
Cancer Management in Small Animal Practice.
Missouri. Saunders Elsevier 2010, p 275-280.

Tumors of the mammary gland, in. Lana SE, Rutteman GR, Withrow SJ. Withrow SJ, Vail DM (eds):
Withrow & MacEwen’s Small Animal Clinical Oncology
. Missouri, Saunders Elsevier, 2007, pp 619-628

Mammary Gland Neoplasia, Dog. Balkman C, in Cote E (2
^nd
ed),
Clinical Veterinary Advisor: Dogs and Cats.
Missouri, Mosby Elsevier, 2011, p 692-694.

Canine Mammary Gland Tumors. Sorenmo K.
Vet Clin Small Anim
33: 573-596, 2003.

Mammary Cancer. Henry CJ, in Bonagura JD, Twedt DC (ed):
Kirk’s Current Veterinary Therapy XIV.
Missouri. Saunders Elsevier 2009, p 363-368.

A population-based case-control study of canine mammary tumours and clinical use of medroxyprogesterone acetate. Stovring M, Moe L, Glattre E.
APMIS
105:590, 1997.

Mammary gland tumors in male dogs. Saba CF, Rogers KS, Newman SJ, et al.
J Vet Intern Med
21:1056, 2007.

Factors influencing canine mammary cancer development and postsurgical survival. Schneider R, Dorn CR, Taylor DON.
J Natl Cancer Inst
43(6):1249, 1969.

Body confirmation, diet and risk of breast cancer in pet dogs: a case-control study. Sonnenschein EG, Glickman LT, Goldschmidt MH, et al.
Am J Epidemiol
133:694, 1991.

Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma. Heller DA, Clifford CA, Goldschmidt MH, et al.
Vet Pathol
. 42(6):776-80. 2005

Meta-analysis: dietary fat intake, serum estrogen levels, and the risk of breast cancer. Wu AH, Pike MC, Stram DO.
J Natl Cancer Inst
. 17;91(6):529-34. 1999

Relation between habitual diet and canine mammary tumors in a case-control study. Perez Alenza MD, Rutteman GR, Pena L, et al.
J Vet Intern Med
12:132, 1998.

Factors influencing the incidence and prognosis of canine mammary tumours. Perez Alenza MD, Pena L, del Castillo N, Nieto AI.
J Small Anim Pract
41:287, 2000.

Prognostic factors in canine mammary tumours: a multivariate study of 202 consecutive cases. Hellmen E, Bergstrom R, Holmberg L, et al.
Vet Pathol
30:20, 1993

Histopathologic and dietary prognostic factors for canine mammary carcinoma. Shofer FS, Sonnenschein EG, Goldschmidt MH, et al.
Breast Cancer Res Treat
. 13(1):49-60. 1989

The lymph drainage of the neoplastic mammary glands in the bitch: a lymphographic study. Patsikas MN, Karayannopoulou M, Kaldrymidoy E, et al.
Anat Histol Embryol.
2006 Aug;35(4):228-34.

Effect of spaying and timing of spaying on survival of dogs with mammary carcinoma. Sorenmo KU, Shofer FS, Goldschmidt MH.
J Vet Intern Med
14:266, 2000.

Clinicopathological survey of 101 canine mammary gland tumors: differences between small-breed dogs and others. Itoh T, Uchida K, Ishikawa K, et al.
J Vet Med Sci
67:345, 2005.

Adjuvant post-operative chemotherapy in bitches with mammary cancer. Karayannopoulou M, Kaldrymidou E, Constantinidis TC, et al.
J Vet Med A Physiol Pathol Clin Med
. 48(2):85-96. 2001